QURE Earnings Date: Nov 4, 2026 (Estimated) — uniQure N.V.
NASDAQ
Updated
When is QURE's next earnings date?
uniQure N.V. (QURE) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.92 on revenue of $6.2M.
How did QURE do in its last earnings report?
In its most recent report on Jul 29, 2026 (Q2 2026), uniQure N.V. posted EPS of -$1.22 versus the -$0.75 estimate, a miss of 62.7%. Revenue was $5.8M against a $5.2M estimate. The stock's 1-day post-earnings move was +9.3%.
How much does QURE stock move after earnings?
QURE beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.2% (up or down) in the day after earnings.
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 | Q2 2026 | -0.75 | -1.22 | -62.67% | $5.8M | ❌ Miss | +9.30% | +19.15% | +38.98% |
| 2026-05-05 | Q1 2026 | -0.78 | -0.85 | -8.97% | $3.6M | ❌ Miss | +2.32% | +33.66% | +44.49% |
| 2026-03-02 | Q4 2025 | -0.85 | -0.56 | +34.12% | $5.6M | ✅ Beat | -32.82% | -8.70% | -5.76% |
| 2025-11-10 | Q3 2025 | -0.79 | -1.38 | -74.68% | $3.7M | ❌ Miss | -5.90% | +7.52% | -25.22% |
| 2025-07-29 | Q2 2025 | -0.81 | -0.69 | +14.81% | $5.3M | ✅ Beat | -8.68% | -8.08% | +5.41% |
| 2025-02-27 | Q4 2024 | -0.51 | -1.50 | -194.12% | $5.2M | ❌ Miss | +3.43% | +3.60% | +12.47% |
| 2024-11-05 | Q3 2024 | -1.00 | -0.91 | +9.00% | $2.3M | ✅ Beat | +8.99% | +37.77% | +13.13% |
| 2024-08-01 | Q2 2024 | -1.25 | -1.16 | +7.20% | $11.1M | ✅ Beat | -2.35% | -7.05% | -18.80% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY25 · $5.6M total
| Segment | Share | Revenue | YoY | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 |
|---|---|---|---|---|---|---|---|
| License revenues | 99.2% | $5.5M | +11.6% | $1.9M | $2.1M | $5.0M | $1.6M |
| Collaboration revenues | 0.8% | $45K | -81.7% | $7.1M | $200K | $246K | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.